Safflower Oil Emulsion Administration During Parenteral Nutrition in the Preterm Infant. 2. Effect on Triglyceride and Free Fatty Acid Levels

1985 ◽  
Vol 4 (5) ◽  
pp. 804-807 ◽  
Author(s):  
Richard J. Cooke ◽  
Marlene Buis ◽  
Paulus Zee ◽  
Yu-Yan Yeh
1982 ◽  
Vol 10 (3) ◽  
pp. 258-264 ◽  
Author(s):  
D. G. Tabrett ◽  
G. D. Phillips

A new intravenous safflower oil emulsion (Liposyn, Abbott) was administered to 23 patients receiving total parenteral nutrition. In a prospective clinical trial, 500 ml of the 10% emulsion was administered each day for a minimum of 10 days. Plasma fatty acid estimations showed a rise in linoleic acid in 22 patients, and a fall in triene/tetraene ratio (a guide to the presence of essential fatty acid deficiency), in 17 patients within four days of commencement of the infusion. Administration of Liposyn prevented the development of biochemical evidence of essential fatty acid deficiency. There were no clinical side effects attributable to the emulsion. Elevation of serum triglyceride and liver enzyme concentrations occurred in some patients.


1983 ◽  
Vol 198 (6) ◽  
pp. 725-735 ◽  
Author(s):  
JÖRGEN NORDENSTRÖM ◽  
YVON A. CARPENTIER ◽  
JEFFREY ASKANAZI ◽  
ARNOLD P. ROBIN ◽  
DAVID H. ELWYN ◽  
...  

1983 ◽  
Vol 7 (3) ◽  
pp. 251-253 ◽  
Author(s):  
Gilbert J. Burckart ◽  
Peter F. Whitington ◽  
Deborah K. Halbrehder ◽  
Richard A. Helms

Author(s):  
Lauren C Frazer ◽  
Camilia R Martin

Parenteral lipid emulsions are a necessary component of nutrition for extremely low gestational age newborns until adequate levels of enteral intake are established. Historically, Intralipid, a 100% soybean oil emulsion, has filled this role. Newer multicomponent lipid emulsions containing a mixture of other oils, including olive oil and fish oil, are now available as options, although the regulatory approval for use in neonates varies worldwide. When dosed at currently published recommendations, each of these lipid emulsions meets total fat and energy requirements without a risk of essential fatty acid deficiency. Thus, when choosing which lipid emulsion to provide, the answer must be based on the metabolic differences induced as a result of these fatty acid-rich emulsions and whether the emulsions provide a health advantage or pose a health risk. The questions of induced fatty acid profiles, health benefit and health risk are discussed sequentially for multicomponent lipid emulsions. Despite the growing acceptance of multicomponent lipid emulsions, there is concern regarding changes in blood fatty acid levels and potential health risk without strong evidence of benefit. There remains no ideal parenteral lipid emulsion option for the preterm infant. Standardising future animal and human studies in lipid delivery with the inclusion of lipid metabolism data will iteratively provide answers to inform the optimal lipid emulsion for the preterm infant.


Sign in / Sign up

Export Citation Format

Share Document